10 minutes read
Relapsed and refractory (r/r) hematologic malignancies — hematologic cancers that have progressed despite first-line treatment or remain uncontrolled after second or third-line therapy — have historically been the patient group with the worst prognosis. But over the past 5 years, the emergence of breakthrough therapies — CAR-T, bispecific antibodies, novel small molecule targeted drugs, and haploidentical HSCT sequential strategies — has substantially changed r/r hematologic disease outcomes. China is among the global providers of these therapies — with 6 NMPA-approved CAR-T products, multiple approved bispecific antibodies, the Beijing Protocol haploidentical HSCT allowing patients without HLA-matched donors to receive transplant, and pricing approximately 1/3 to 1/10 of US costs. This article provides a complete treatment pathway in China for r/r hematologic disease patients — organized by disease, including sequential strategies, and practical access pathways.
The Special Challenge of Relapsed and Refractory Hematologic Malignancies
Why r/r patients are harder to treat than newly diagnosed:
- Resistance: tumor clones surviving first-line treatment typically have resistance mechanisms
- Disease progression: after multi-line treatment failure, tumor burden is often larger and more disseminated
- Normal hematopoietic system damage: cumulative damage to bone marrow from multi-line chemotherapy
- Organ function decline: long-term treatment effects on liver, kidney, cardiac function
- Quality of life decline: reduced performance status, malnutrition, psychological burden
Practical implication for patients: r/r treatment requires a complete multi-modality strategy — single drugs or single treatments rarely deliver durable remission. China’s advantage is providing simultaneous access to CAR-T, bispecific antibodies, HSCT, and other modern treatments, with substantial pricing advantages that make long-term sequential treatment economically feasible.
China-Available Treatment Options by Disease
1. Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
China-available options:
CAR-T (see Article 21):
- Axi-cel (Yescarta, Fosun Kite) — NMPA approved June 2021
- Relma-cel (Carteyva, JW Therapeutics) — NMPA approved September 2021
- A complete CAR-T course in China is approximately $160K–$220K USD (see Article 21)
Bispecific antibodies:
- Glofitamab (Roche Columvi) — NMPA approved November 2023 [1]
- Used for patients with relapsed/refractory DLBCL who have received at least 2 lines of systemic therapy
- Advantage over CAR-T: off-the-shelf product (immediate use, no individualized manufacturing wait)
Other options:
- BTK inhibitors (especially for MYD88 / CD79B mutation subtypes)
- Anti-CD20 + chemotherapy reinduction
- Autologous HSCT (specific indications)
Typical treatment pathway decisions:
| Patient Situation | Recommended Pathway |
|---|---|
| 2nd-line failure + good performance status | CAR-T (first choice) or glofitamab (if unable to wait for CAR-T manufacturing) |
| Multi-line failure + poor performance status | Glofitamab off-the-shelf (no manufacturing wait) |
| Post-CAR-T relapse | Glofitamab or clinical trial |
2. Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL)
China-available options:
- Inaticabtagene autoleucel CAR-T (CASI Pharma) — NMPA approved November 2023, China’s first B-ALL CAR-T (see Article 21)
- Blinatumomab (bispecific T-cell engager) — adult NMPA approved December 2020, pediatric May 2022 [2]
- Beijing Protocol haploidentical HSCT — see Article 24, allowing parents/children as donors
- Bridging to HSCT after treatment is a common strategy
Typical sequential pathway:
- CAR-T or blinatumomab achieves deep remission
- Sequential haploidentical HSCT for consolidation
- Zhejiang 1st Hospital Huang He team NEJM 2024 data: CD7 CAR-T + allogeneic HSCT sequential (no GVHD prophylaxis), 10 r/r T-ALL/LBL patients, 1-year OS 68% [3]
3. Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)
China-available options:
- Venetoclax (BCL2 inhibitor) + azacitidine / decitabine — venetoclax conditionally NMPA approved December 2020 [4]
- China’s only approved BCL2 inhibitor
- Suitable for elderly or frail patients unsuitable for intensive chemotherapy
- Beijing Protocol haploidentical HSCT — core curative therapy
- Some r/r AML patients can enroll in NK cell therapy or novel CAR-T clinical trials
Typical treatment pathway decisions:
| Patient Situation | Recommended Pathway |
|---|---|
| Good performance + suitable donor | Intensive reinduction → allo-HSCT |
| Poor performance or elderly | Venetoclax + hypomethylating agent |
| Multi-line failure + awaiting transplant | Venetoclax bridge to HSCT |
4. Relapsed/Refractory Multiple Myeloma (r/r MM)
China-available options (after ≥3 prior lines of treatment):
BCMA CAR-T (China has 3 NMPA-approved, see Article 21):
- Equecabtagene autoleucel (IASO/Innovent, June 2023)
- Zevor-cel (CARsgen, March 2024)
- Cilta-cel (Legend/Johnson & Johnson, August 2024)
Teclistamab (BCMA × CD3 bispecific antibody):
- NMPA approved June 2024 [5]
- Off-the-shelf product, immediate use
- For r/r MM after at least 3 prior lines of treatment
Other availability:
- Second-generation proteasome inhibitors (carfilzomib)
- Immunomodulatory drugs (lenalidomide, pomalidomide)
- Daratumumab (CD38 monoclonal antibody)
- Selinexor (XPO1 inhibitor)
Typical treatment pathways:
| Patient Situation | Recommended Pathway |
|---|---|
| 3rd-line failure + suitable for CAR-T | BCMA CAR-T (best deep remission) |
| Unable to wait for CAR-T manufacturing | Teclistamab bispecific as bridge |
| Post-CAR-T relapse | Teclistamab or daratumumab re-challenge |
5. Relapsed/Refractory Hodgkin Lymphoma (r/r HL)
China-available options:
- Brentuximab vedotin (Adcetris) ADC — NMPA approved May 2020 for CD30+ HL/sALCL [6]
- PD-1 inhibitors — multiple Chinese domestic PD-1 drugs have NMPA-approved r/r HL indications (see Article 27)
- Autologous HSCT — standard consolidation for HL relapse after first-line chemotherapy
- Allogeneic HSCT — curative option after multi-line failure
Typical treatment pathway:
- PD-1 ± brentuximab vedotin to achieve remission
- Autologous HSCT for consolidation
- Multi-line failure: allogeneic HSCT
6. Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
China-available options:
- Relma-cel CAR-T — NMPA added MCL indication August 2024 [7]
- BTK inhibitors (zanubrutinib, orelabrutinib, acalabrutinib — see Article 27)
- Venetoclax (selected cases)
- Autologous HSCT
China’s Unique Advantages in r/r Treatment
Advantage 1 · Beijing Protocol Haploidentical HSCT
See Article 24 — allowing parents, children, and siblings to serve as donors, this is the key curative option for r/r hematologic patients without HLA-matched donors.
Advantage 2 · CAR-T + HSCT Sequential Strategy
China leads internationally in “CAR-T bridge to HSCT” strategy [3]:
- HSCT performed immediately after CAR-T achieves deep remission
- Substantially reduces relapse rates
- Zhejiang 1st Hospital Huang He team 2024 NEJM CD7 CAR-T + alloHSCT data is the international benchmark
Advantage 3 · “Off-the-Shelf” Value of Bispecific Antibodies
CAR-T requires 10–14 days of individualized manufacturing — for rapidly progressing patients, this wait may not be feasible. Bispecific antibodies (glofitamab, teclistamab, blinatumomab) are off-the-shelf products — they can serve as bridging therapy while waiting for CAR-T manufacturing.
Advantage 4 · Pricing Makes Long-Term Sequential Treatment Feasible
r/r hematologic disease typically requires multi-line sequential treatment (CAR-T + HSCT + long-term immunosuppression + maintenance therapy, etc.). China’s overall pricing is approximately 1/3–1/10 of US — making long-term treatment economically sustainable.
China’s Leading r/r Hematologic Disease Centers
(Detailed introductions in Articles 21 and 24)
- Peking University People’s Hospital Hematology (Academician Huang Xiaojun / Professor Zhang Xiaohui Team) — Beijing Protocol haploidentical HSCT global leader
- Zhejiang University 1st Affiliated Hospital (Professor Huang He Team) — CD7 CAR-T + alloHSCT NEJM 2024
- Soochow University 1st Affiliated Hospital (Professor Wu Depei) — National Clinical Research Center for Hematologic Disorders + ASHI-accredited high-resolution HLA laboratory
- Institute of Hematology and Blood Diseases Hospital (Tianjin) — national hematologic Tier-3A specialty hospital
- Shanghai Ruijin Hospital Hematology (Professor Zhao Weili Team) — strong in lymphoma targeted therapy
- Peking Union Medical College Hospital Hematology — strong comprehensive capability
International Patient Pathway for r/r Hematologic Treatment in China
Best-suited international patient profile:
- First- or second-line treatment failure in home country, with established r/r diagnosis
- Long CAR-T waiting time in home country (particularly Europe, often months)
- CAR-T or HSCT pricing unaffordable in home country
- No suitable HLA-matched HSCT donor in home country — Beijing Protocol allows parents/children as donors
- China-available bispecific antibodies or novel drugs not approved in home country
Typical time in China:
| Treatment | Time in China |
|---|---|
| CAR-T (see Article 21) | 6–9 weeks |
| Haploidentical HSCT (see Article 24) | 10–14 weeks |
| CAR-T + HSCT sequential | 12–20 weeks |
| Bispecific antibody course | 6–12 weeks (plan-dependent) |
Practical steps (synthesized):
- Remote second opinion evaluation (Article 9) — determine which treatment best fits
- MDT consultation (Article 10) — hematology + oncology + transplant joint planning
- Complete records preparation (Article 7) — especially pathology slides (Article 19) and genetic testing results
- Arrive in China + treatment + long-term remote follow-up after return
Common Questions
My DLBCL relapsed after CAR-T at home — what can China still offer? Glofitamab (China NMPA approved November 2023) is the primary option after CAR-T failure. Other options include a different CAR-T product, clinical trial combination drugs, etc.
I don’t have a matched HSCT donor — can Beijing Protocol really let my parents donate? Yes (see Article 24). The core breakthrough of Beijing Protocol is enabling haploidentical (half-match) donors to perform transplant — your parents, children (100% half-matched), and siblings (50% probability of half-matching) all qualify, with outcomes comparable to matched transplant.
CAR-T or HSCT — which first? For most r/r ALL and r/r MM patients, CAR-T first to achieve deep remission, then bridge to HSCT consolidation is currently the optimal strategy. Specific sequencing requires MDT evaluation.
What options remain for elderly r/r AML patients? Venetoclax + azacitidine / decitabine is the first choice — achieving remission without intensive chemotherapy; some patients can bridge to HSCT.
What’s the advantage of bispecific antibodies over CAR-T? Off-the-shelf product + immediate use — no 10-14 day individualized manufacturing wait; outpatient or short hospital stay administration — shorter than the CAR-T inpatient monitoring period; can be repeated — CAR-T is typically a one-time treatment.
Roughly how much does r/r hematologic treatment in China cost?
- CAR-T single course approximately $160K–$220K USD
- Haploidentical HSCT approximately $50K–$80K USD
- Bispecific antibody course + long-term maintenance requires specific assessment
- Overall approximately 1/3 to 1/10 of US
Can long-term follow-up after r/r treatment be done after returning home? Yes. The critical step is establishing immediate post-treatment coordination with your home country hematology / transplant center — MedCareInChina facilitates remote coordination. Most r/r hematologic treatments require ≥2 years of long-term follow-up.
Bottom Line
Core value of r/r hematologic disease treatment in China:
- Multiple modern treatments simultaneously accessible: CAR-T, bispecific antibodies, haploidentical HSCT, novel targeted drugs
- Beijing Protocol enables transplant for patients without matched donors
- CAR-T + HSCT sequential strategy internationally leading (Zhejiang 1st NEJM 2024)
- Pricing advantages make long-term sequential treatment economically feasible
Best-suited international patients:
- r/r DLBCL, r/r B-ALL, r/r AML, r/r MM, r/r HL, r/r MCL
- Long CAR-T waiting time or unaffordable cost in home country
- No HLA-matched HSCT donor, wanting to use Beijing Protocol haploidentical approach
- Need home country-unapproved bispecific antibodies (such as teclistamab, glofitamab)
Total time in China: 6–20 weeks (depending on treatment combination)
If you or a family member has r/r hematologic disease, MedCareInChina matches the most appropriate Chinese hematology center and treatment sequence based on your specific diagnosis, prior treatment, and genetic testing results — and clearly identifies expected timeline, estimated cost, and long-term management pathway.
→ Send your case to hello@medcareinchina.com
See Service & Refund Policy and Medical Disclaimer for service boundaries.
Sources
- Glofitamab China NMPA approval — Roche Columvi, November 2023 NMPA approval for r/r DLBCL. Source: https://www.ainvest.com/news/roche-glofitamab-approved-china-relapsed-lymphoma-2505/
- Blinatumomab China NMPA approval — Adult December 2020, pediatric May 2022. Source: https://www.businesswire.com/news/home/20201207005670/en/
- Zhejiang 1st CD7 CAR-T + alloHSCT sequential (NEJM 2024) — Huang H, et al. NEJM April 2024. 10 r/r CD7+ T-ALL/LBL patients, 1-year OS 68%, DFS 54%. Sources: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2313812 ; https://pubmed.ncbi.nlm.nih.gov/38657244/
- Venetoclax China NMPA approval — December 2020 conditional approval for CLL and AML (combined with azacitidine / decitabine). Sources: https://news.abbvie.com/2020-10-16- ; https://pmc.ncbi.nlm.nih.gov/articles/PMC10149010/
- Teclistamab China NMPA approval — June 2024 NMPA approval for r/r MM. Source: https://www.medthority.com/news/2024/6/nmpa-china-approves-tecvayli-
- Brentuximab vedotin (Adcetris) China NMPA approval — May 2020 NMPA approval for CD30+ HL/sALCL. Source: Takeda China https://www.takeda.com/newsroom/newsreleases/2020/
- Relma-cel MCL indication — NMPA added MCL indication August 2024. Source: Lymphoma Hub https://lymphomahub.com/medical-information/relmacabtagene-autoleucel-receives-china-nmpa-supplementary-biological-application-approval-for-rr-mcl
- Beijing Protocol Haploidentical HSCT — Peking University People’s Hospital Academician Huang Xiaojun. Covers more than half of global haploidentical transplant cases, 3-year OS increased from ~20% to ~70%. Sources: https://pubmed.ncbi.nlm.nih.gov/31431695/ ; PKU news https://newsen.pku.edu.cn/news_events/news/people/13991.html
- Soochow University 1st Affiliated Hospital Hematology Institute — National Clinical Research Center for Hematologic Disorders, ASHI-accredited HLA laboratory. Source: China Daily https://govt.chinadaily.com.cn/s/201904/23/WS5cbeb6dd498e079e6801ec4d/
- Institute of Hematology and Blood Diseases Hospital (Tianjin) — CAMS&PUMC’s only national hematologic Tier-3A specialty hospital. Source: https://en.wikipedia.org/wiki/Institute_of_Hematology_and_Blood_Diseases_Hospital,CAMS%26_PUMC
